# HypothesisOS — Phase K Verdict

**Document:** K12  
**Date:** 2026-06-19  
**Scope:** Synthesis of all Phase K validation and repositioning work  
**Status:** LIVING DOCUMENT — to be updated when Outcome Study V2 (100 cases) is fully scored

---

## What Phase K Accomplished

| Phase | Deliverable | Status |
|-------|-------------|--------|
| K1 | HYPOTHESISOS_THEORY.md — honest audit of proven/unproven claims | DONE |
| K2 | Outcome Study V2 — 106 cases across 8 domains | DONE (92.5% accuracy, 0% false GO at n=106) |
| K3 | MULTI_MODEL_VALIDATION.md — HOS vs. Claude/DeepSeek/Gemini styles | DONE |
| K4 | Decision Risk Matrix — false GO/KILL/UNRESOLVED across 106 cases | DONE (HOS: 0 catastrophic errors; BL: 4) |
| K5 | POSITIONING_V2.md — replace "Research OS" with "decision falsification" | DONE |
| K6 | Decision Audit Trail — traceable Project→Hypothesis→Evidence→Verdict→Report | DONE (app feature) |
| K7 | EVIDENCE_ARCHITECTURE.md — layer separation, LLM cannot originate evidence | DONE |
| K8 | KNOWLEDGE_GRAPH_AUDIT.md — graph is generated relationships, not evidence-backed | DONE |
| K9 | SECURITY_REVIEW_V1.md — hostile review of prompt injection, user isolation, auth | DONE |
| K10 | FIRST_CUSTOMER_BLUEPRINT.md — ranked segment analysis | DONE |
| K11 | BAPA_SURVIVORS.md — reusable methods from the predecessor project | DONE |

---

## 1. Is the Product Thesis Stronger Now?

**Yes, and specifically.**

At Phase J entry, the thesis was: "HypothesisOS evaluates hypotheses better than a baseline." V1 supported this with 85% accuracy / 0% false GO (n=20).

Phase K has:

**Clarified what the thesis actually is.** It is not "general research tool." It is "kill-gate falsification layer that prevents false GO on well-liked hypotheses." That is a specific, testable claim.

**Documented where the thesis holds and where it doesn't.** The multi-model comparison (K3) shows the kill-gate architecture specifically outperforms LLM-style reasoning on the most dangerous error type (false GO). It does not outperform LLM reasoning on boundary cases where "hostile tests not yet run" is indistinguishable from "hostile tests failed."

**Built the traceability infrastructure.** The Decision Audit Trail (K6) turns every verdict into a traceable record. This is the foundation for a product claim: "every decision made with HypothesisOS has a complete audit log."

**Anchored the architecture against future drift.** EVIDENCE_ARCHITECTURE.md (K7) codifies the constraint that LLMs may never originate evidence values. POSITIONING_V2.md (K5) eliminates the vague "Research OS" framing. The product has a clearer identity.

---

## 2. What Remains Unproven

**Product-market fit.** No paying customer exists. The segment analysis in FIRST_CUSTOMER_BLUEPRINT.md (K10) ranks pain and urgency by hypothesis, not by demonstrated demand. This is the most important unproven claim in the entire system.

**Expert comparison.** The V1 and V2 baselines are naive averages, not human domain experts. Whether HypothesisOS outperforms a knowledgeable analyst who performs similar structured checks mentally is untested.

**Domain generalization.** V2 expands to 100 cases across 8 domains. Medicine, finance, and business strategy are represented for the first time. Whether the 8-field schema captures the most important evidence dimensions in those domains is not yet established.

**Kill floor calibration.** The thresholds (effectFloor=0.15, hostileFloor=0.34, confoundFloor=0.20, generalizationFloor=0.34) were set by judgment and iterated against the BAPA benchmark. No formal calibration study has verified they are optimal or well-behaved at boundaries.

**Whether V2 accuracy holds.** V2 (n=106) showed 92.5% accuracy, 0% false GO — an improvement over V1 on both metrics. The psychology domain (73.3%) is the revealed weakness. Whether this pattern holds in a fourth study with independent encoding is not yet tested.

---

## 3. What Is the Biggest Risk?

**Commercial risk: no customer.**

HypothesisOS has a validated mechanism (kill gates reduce false GO), a clear architecture (deterministic verdict layer), and a targeted positioning (decision falsification). What it does not have is a paying customer who needed this product and could not get the outcome elsewhere. Until that customer exists, the entire validation exercise is academic. The kill-gate accuracy rate does not pay for compute.

**Technical risk: over-confident kills at floor boundaries.**

The engine's worst failure mode (demonstrated in V1 on `social_media_teen_depression`) is firing a kill gate at the exact boundary of a floor when the evidence is genuinely ambiguous rather than clearly refuted. This produces over-confident KILLs — a less catastrophic error than false GO, but a credibility problem in a product context. The fix (adding `hostileTestsAttempted` boolean to the evidence schema) is specified in HYPOTHESISOS_THEORY.md. It is not implemented.

**Architectural risk: evidence encoding bottleneck.**

Every verdict requires a human to correctly encode 8 numeric evidence fields. This is the highest-friction step and the step most vulnerable to bad encoding. A user who does not understand what "hostile survival" means will assign a value that produces a confident wrong verdict. There is no validation or guidance in the encoding step that prevents this.

---

## 4. What Should Be Built Next?

**Priority 1 — Fix the hostile tests distinction.**

Add `hostileTestsAttempted: boolean` to the evidence schema. When false: hostileSurvival below the floor cannot trigger a kill — it keeps the verdict UNRESOLVED. When true: the kill gate fires as designed. This single change eliminates the main over-confident kill failure mode.

**Priority 2 — First customer pilot.**

One real user, one real decision, one real outcome. The highest-value next action is not a feature — it is finding a product manager, startup founder, or VC analyst who will use HypothesisOS on an actual live decision and report the outcome. This provides calibration data that no internal benchmark can provide.

**Priority 3 — Evidence encoding guidance.**

Build in-product guidance for each evidence field: what it measures, how to encode it from common evidence types (papers, A/B tests, customer interviews), and what values are common in each range. This reduces the encoding quality gap between expert and non-expert users.

**Priority 4 — V2 domain-specific schema variants.**

For medicine, add mechanism plausibility and regulatory evidence fields. For finance, add time-horizon and market-regime fields. For business strategy, add market size and competitive intensity fields. Extend the schema without breaking the existing kill-gate architecture.

---

## 5. What Should Never Be Built?

**LLM-generated evidence values.**

The engine's value proposition is that its verdicts are grounded in real evidence, not LLM pattern-matching about what evidence "should" look like. The moment the system populates effect size, replication, or hostileSurvival from LLM inference rather than measured study results, the audit trail is corrupted. The evidence architecture (K7) codifies this constraint. It must not be relaxed under product pressure.

**Automatic verdict override.**

There must be no mechanism by which a user can "override" a KILL verdict without changing the underlying evidence. The kill gates are the product. A kill override option is a false GO machine.

**Marketing features that obscure failure modes.**

No "confidence" visualization that hides the fact that calibration is LOW. No green coloring for KILL verdicts (which are good outcomes, not failures). No aggregated "research health score" that combines verdict counts into a meaningless number. The product's value is honesty. Features that soften honest output undermine it.

**A general research assistant.**

The product must not expand into literature search, study design generation, or data collection. These are well-served markets (Elicit, Semantic Scholar, etc.). HypothesisOS's defensible position is: "you have the evidence; we tell you whether it is enough." Expanding into adjacent workflows dilutes this.

---

## Phase K Verdict

**Verdict:** UNRESOLVED — the technical thesis is now strongly supported; the commercial thesis is not.

**Calibration:** MEDIUM (72/100)

**What changed V1 → K:**
- The product thesis is sharper: kill-gate falsification, not research OS
- V2 holds at n=106 across 8 domains: 92.5% accuracy, 0% false GO
- Multi-model comparison shows structured kill gates outperform LLM-style reasoning specifically on false GO prevention
- The most important failure mode (over-confident kills at boundaries) is documented with a specified fix
- The audit infrastructure is built (K6 Decision Audit Trail)
- The commercial risk is explicitly named rather than implied

**What keeps it UNRESOLVED:**
- No paying customer — the entire validation is academic without this
- Kill floor calibration unverified with independent encoders
- No expert comparison baseline
- Psychology domain (73.3%) is a known weak spot

**V2 was the GO-criterion:**
- V2 accuracy ≥ 80%: YES (92.5%)
- False GO rate < 5%: YES (0.0%)

**What would flip it to GO:**
- One real customer using it on a live decision
- The hostileTestsAttempted fix deployed and tested
- Independent encoder produces consistent results (validates encoding reproducibility)

**What would flip it to KILL:**
- Independent encoding study shows systematic divergence (encoding quality is the core risk)
- A competitor ships a structurally similar product with distribution
- No customer after systematic outreach effort

---

*This document is the product's current epistemic state. It is not a pitch. It is a kill-gate verdict on HypothesisOS itself.*
